AR115083A1 - Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 - Google Patents
Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1Info
- Publication number
- AR115083A1 AR115083A1 ARP190101204A ARP190101204A AR115083A1 AR 115083 A1 AR115083 A1 AR 115083A1 AR P190101204 A ARP190101204 A AR P190101204A AR P190101204 A ARP190101204 A AR P190101204A AR 115083 A1 AR115083 A1 AR 115083A1
- Authority
- AR
- Argentina
- Prior art keywords
- mutein
- fusion proteins
- type
- interferon
- interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente describe proteínas de fusión basadas en citocinas, denominadas bicitocinas (BCs), particularmente formadas por la unión de una muteína agonista de IL2 con un interferón (IFN) tipo 1, enlazados mediante la región Fc de una lgG1 humana mutada y un péptido conector. La combinación de una muteína agonista de IL2 y el IFN tipo 1 en la estructura de las moléculas aquí obtenidas, le confiere propiedades inmunorreguladoras sorprendentes y un efecto terapéutico superior a las citocinas parentales, o a su combinación, lo cual las convierte en moléculas para el tratamiento del cáncer. Se describen además, las composiciones farmacéuticas que comprenden como principio activo las proteínas de fusión aquí descritas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2018000039A CU24554B1 (es) | 2018-05-07 | 2018-05-07 | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR115083A1 true AR115083A1 (es) | 2020-11-25 |
Family
ID=68467792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101204A AR115083A1 (es) | 2018-05-07 | 2019-05-07 | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11926654B2 (es) |
EP (1) | EP3792277A1 (es) |
JP (1) | JP7423607B2 (es) |
CN (1) | CN112218884A (es) |
AR (1) | AR115083A1 (es) |
BR (1) | BR112020022511A2 (es) |
CA (1) | CA3098653A1 (es) |
CU (1) | CU24554B1 (es) |
TW (1) | TWI821287B (es) |
WO (1) | WO2019214757A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021523741A (ja) | 2018-05-14 | 2021-09-09 | ウェアウルフ セラピューティクス, インコーポレイテッド | 活性化可能なインターロイキン12ポリペプチド及びその使用方法 |
CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
EP3856764A4 (en) | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | MASKED CYTOKINE POLYPEPTIDES |
KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2023141555A2 (en) * | 2022-01-21 | 2023-07-27 | Aetio Biotherapy, Inc. | Immunoconjugates of interleukin-2 mutant polypeptides with antibodies |
CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
KR20020018197A (ko) | 1999-05-19 | 2002-03-07 | 추후보정 | Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
DK1200479T3 (da) | 1999-08-09 | 2006-05-15 | Emd Lexigen Res Ct Corp | Multiple cytokin-antistof-komplekser |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
CN102041263B (zh) | 2010-02-08 | 2013-01-09 | 河南省动物疫病预防控制中心 | 鸡α干扰素/白细胞介素2嵌合基因 |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
EP3211001B1 (en) | 2010-12-22 | 2020-10-07 | The Board of Trustees of the Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
WO2014100014A1 (en) * | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-2 complexes with antibody to augment il-2 therapy |
CN104877029A (zh) * | 2015-04-24 | 2015-09-02 | 昆明理工大学 | 一种Vimentin-Fc融合蛋白及其应用 |
CN106397607A (zh) * | 2016-09-13 | 2017-02-15 | 河南师范大学 | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 |
CN107286254A (zh) | 2017-08-09 | 2017-10-24 | 芜湖英特菲尔生物制品产业研究院有限公司 | 犬白蛋白‑干扰素α‑白介素2融合蛋白、制备方法及其编码基因、一种犬长效干扰素 |
CN107245108A (zh) | 2017-08-09 | 2017-10-13 | 芜湖英特菲尔生物制品产业研究院有限公司 | 牛白蛋白‑干扰素α‑白介素2融合蛋白、制备方法及其编码基因、一种牛长效干扰素 |
-
2018
- 2018-05-07 CU CU2018000039A patent/CU24554B1/es unknown
-
2019
- 2019-03-05 US US17/052,912 patent/US11926654B2/en active Active
- 2019-05-03 BR BR112020022511-8A patent/BR112020022511A2/pt unknown
- 2019-05-03 EP EP19729611.4A patent/EP3792277A1/en active Pending
- 2019-05-03 CN CN201980031020.6A patent/CN112218884A/zh active Pending
- 2019-05-03 JP JP2021512997A patent/JP7423607B2/ja active Active
- 2019-05-03 WO PCT/CU2019/050003 patent/WO2019214757A1/es unknown
- 2019-05-03 CA CA3098653A patent/CA3098653A1/en active Pending
- 2019-05-06 TW TW108115578A patent/TWI821287B/zh active
- 2019-05-07 AR ARP190101204A patent/AR115083A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112020022511A2 (pt) | 2021-02-09 |
CU24554B1 (es) | 2021-11-04 |
CA3098653A1 (en) | 2019-11-14 |
JP2021522861A (ja) | 2021-09-02 |
US11926654B2 (en) | 2024-03-12 |
US20210238246A1 (en) | 2021-08-05 |
EP3792277A1 (en) | 2021-03-17 |
TWI821287B (zh) | 2023-11-11 |
WO2019214757A1 (es) | 2019-11-14 |
CU20180039A7 (es) | 2019-12-03 |
TW202014431A (zh) | 2020-04-16 |
CN112218884A (zh) | 2021-01-12 |
JP7423607B2 (ja) | 2024-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR115083A1 (es) | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 | |
CL2019003390A1 (es) | Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer | |
NZ761434A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
MX2019001185A (es) | Polipeptidos inmunomoduladores y composiciones y metodos relacionados. | |
BR112017007816A2 (pt) | composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas | |
CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
BR112018076437A2 (pt) | interferon porcino peguilado e seus métodos de utilização | |
CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
JP2019013232A5 (es) | ||
EA201591766A1 (ru) | Мутеины интерлейкина-2 для экспансии регуляторных т-клеток | |
PE20190436A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 | |
AR099289A1 (es) | Proteínas de fusión de interleucina-2 y usos de las mismas | |
EA201692103A1 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
PE20200496A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
AR079197A1 (es) | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas | |
EA200800159A1 (ru) | РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2) | |
AR103714A1 (es) | Proteínas específicas para pioverdina y pioquelina | |
PE20230849A1 (es) | PROTEINAS DE FUSION INTERLEUCINA-2-Fc Y METODOS DE USO | |
ZA202208999B (en) | Biased il2 muteins methods and compositions | |
PH12015501796A1 (en) | Il-1b inhibitor composition and use thereof | |
MX2021001305A (es) | Anticuerpos anti-cxcr2 y usos de los mismos. | |
CR20230507A (es) | Anticuerpos anti-il-2r agonistas y métodos de uso | |
AR095527A1 (es) | Formulaciones de polipéptido fc-factor ix | |
PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
MX2018016417A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas. |